Aventis Pharma is exiting its rabies vaccine joint venture with Novartis in India.
Aventis informed the Bombay Stock Exchange that it would sell its 49% holding in the venture, Chiron Behring Vaccines, to Novartis Pharma for about $22.4 million. The sale is expected...